Prospective, Open-label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor who Have Acute Major Bleeding (ANNEXA-4). - ANNEXA-4

PORTOLA PHARMACEUTICALS, INC.0 个研究点目标入组 8 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

阶段: 3 期
状态: 已完成
发起方: PORTOLA PHARMACEUTICALS, INC.
入组人数: 8

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 99（—）

入选标准

•1) Either the patient or his or her medical proxy (or legally acceptable
•designee) has been adequately informed of the nature and risks of the study and has given written
•informed consent prior to Screening;
•2) The patient must be at least 18 years old at the time of Screening;
•3) The patient must have an acute overt major bleeding episode requiring urgent reversal of
•anticoagulation; Acute major bleeding requiring urgent reversal of anticoagulation is defined by at
•least ONE of the following:
•- Acute overt bleeding that is potentially life-threatening, e.g., with signs or symptoms of
•haemodynamic compromise, such as severe
•hypotension, poor skin perfusion, mental confusion, low urine output that cannot be otherwise
•- Acute overt bleeding associated with a fall in haemoglobin level by * 2 g/dL, OR a Hgb * 8 g/dL
•if no baseline Hgb is available;
•- Acute bleeding in a critical area or organ, such as, intra-spinal, pericardial or intracranial.
•4) The patient, for whom the bleeding is intracranial or intraspinal must have undergone a CT or
•MRI scan demonstrating the bleeding.
•5) The patient received or is believed to have received one of the following within 18 hours prior
•to andexanet administration: apixaban, rivaroxaban, edoxaban or enoxaparin (dose of enoxaparin
•*1mg/kg/d).
•6) For patients with ICH, there must be a reasonable expectation that andexanet treatment will
•commence within 2 hours of the baseline
•imaging evaluation.

排除标准

•1) The patient is scheduled to undergo surgery in less than 12 hours
•with the exception of minimally invasive surgery/procedures (e.g.,
•endoscopy, bronchoscopy, central lines, Burr holes);
•2) A patient with ICH has any of the following:
•* Glasgow coma score < 7
•* Estimated intracerebral haematoma volume >60 cc as assessed by the
•3) Patients with visible, musculoskeletal, or intra-articular bleeding as
•the qualifying bleed.
•4) The patient has an expected survival of less than 1 month;
•5) The patient has a recent history (within 2 weeks) of a diagnosed
•thrombotic event (TE) as follows: venous thromboembolism (VTE; e.g.,
•deep venous thrombosis, pulmonary embolism, cerebral venous
•thrombosis), myocardial infarction, disseminated intravascular
•coagulation (DIC), cerebral vascular accident, transient ischemic attack,
•unstable angina pectoris hospitalization, or severe peripheral vascular
•disease within 2 weeks prior to Screening;
•6) The patient has severe sepsis or septic shock at the time of Screening;
•7) The patient is pregnant or a lactating female;
•8) The patient has received any of the following drugs or blood products
•within 7 days or Screening:
•* Vitamin K antagonist (VKA) (e.g., warfarin);
•* Dabigatran;
•* Prothrombin Complex Concentrate products (PCC, e.g., Kcentra®) or
•recombinant factor VIIa (rfVIIa) (e.g., NovoSeven®);
•* Whole blood, plasma fractions
•Note: Administration of platelets or packed red blood cells (PRBCs) is not
•an exclusion criterion;
•9) The patient was treated with an investigational drug <30 days prior
•to Screening.

研究者

发起方

PORTOLA PHARMACEUTICALS, INC.

相似试验

进行中（未招募）

1 期

A study to confirm that andexanet alfa helps to stop severe/ life threatening bleeding in patients, taking a type of anticoagulants called Factor Xa inhibitors.ncontrolled bleeding in patients who have taken either a direct factor Xa inhibitor (novel oral anticoagulants) or an indirect factor Xa inhibitor (low molecular weight heparins).MedDRA version: 20.0Level: LLTClassification code 10075279Term: Anticoagulant reversal therapySystem Organ Class: 100000004865

EUCTR2015-001785-26-BEPortola Pharmaceuticals, Inc.350

进行中（未招募）

1 期

EUCTR2015-001785-26-GBPortola Pharmaceuticals, Inc.350

进行中（未招募）

1 期

EUCTR2015-001785-26-DEPortola Pharmaceuticals, Inc.500

进行中（未招募）

1 期

A study to confirm that andexanet alfa helps to stop severe/ life threatening bleeding in patients, taking a type of anticoagulants called Factor Xa inhibitors.ncontrolled bleeding in patients who have taken either a direct factor Xa inhibitor (novel oral anticoagulants) or an indirect factor Xa inhibitor (low molecular weight heparins).MedDRA version: 18.1Level: LLTClassification code 10075279Term: Anticoagulant reversal therapySystem Organ Class: 100000004865

EUCTR2015-001785-26-FRPortola Pharmaceuticals, Inc.250

进行中（未招募）

1 期

EUCTR2015-001785-26-NLPortola Pharmaceuticals, Inc.350